Stockscreener 앱 받기
1.24
3.13%
-0.04
시장 영업 전:
1.24
전일 마감가:
$1.28
열려 있는:
$1.31
하루 거래량:
355.71K
Relative Volume:
0.92
시가총액:
$52.71M
수익:
$51.13M
순이익/손실:
$-93.80M
주가수익비율:
-0.5561
EPS:
-2.23
순현금흐름:
$-129.10M
1주 성능:
-2.36%
1개월 성능:
-6.06%
6개월 성능:
-68.21%
1년 성능:
-79.80%
1일 변동 폭
$1.22
$1.31
1주일 범위
$1.22
$1.36
52주 변동 폭
$1.20
$8.49
Repare Therapeutics Inc Stock (RPTX) Company Profile
명칭
Repare Therapeutics Inc
전화
(857) 412-7018
주소
7171 FREDERICK BANTING, SAINT-LAURENT, QC
RPTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RPTX
Repare Therapeutics Inc
|
1.24 | 52.71M | 51.13M | -93.80M | -129.10M | -2.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Repare Therapeutics Inc Stock (RPTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-06-09 | 업그레이드 | Stifel | Hold → Buy |
| 2023-02-03 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-01-06 | 개시 | CapitalOne | Overweight |
| 2022-04-12 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-03-17 | 재개 | Goldman | Buy |
| 2021-09-23 | 개시 | Stifel | Buy |
| 2021-09-13 | 개시 | H.C. Wainwright | Buy |
| 2021-06-28 | 개시 | Guggenheim | Buy |
| 2021-03-01 | 개시 | Berenberg | Buy |
| 2020-10-28 | 개시 | Northland Capital | Outperform |
| 2020-07-14 | 개시 | Cowen | Outperform |
| 2020-07-14 | 개시 | Goldman | Neutral |
| 2020-07-14 | 개시 | Morgan Stanley | Overweight |
| 2020-07-14 | 개시 | Piper Sandler | Overweight |
모두보기
Repare Therapeutics Inc 주식(RPTX)의 최신 뉴스
Repare Therapeutics (RPTX) Loses -5.19% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
CNL'S CNRI-H Program Continues Strong Growth Thanks to New Projects With Repare Therapeutics and Defence Therapeutics - Financial Post
CNL’S CNRI-H Program Continues Strong Growth Thanks to New Projects With Repare Therapeutics and Defence Therapeutics - Yahoo Finance
Short Interest in Repare Therapeutics Inc. (NASDAQ:RPTX) Grows By 53.3% - MarketBeat
Layoff Tracker: Notch Therapeutics to ‘Significantly Reduce’ Workforce - BioSpace
Repare Therapeutics eyes Phase III cancer study after Mythic trial success - MSN
The Market Doesn't Like What It Sees From Repare Therapeutics Inc.'s (NASDAQ:RPTX) Revenues Yet As Shares Tumble 26% - Simply Wall St
Repare Therapeutics Announces Strategic Changes and Financial Update - Defense World
Repare Therapeutics Inc. (NASDAQ:RPTX) Shares Acquired by Barclays PLC - Defense World
Stifel cuts Repare Therapeutics target to $3, maintains Buy By Investing.com - Investing.com Canada
Repare Therapeutics stock rating cut to Hold at Bloom Burton By Investing.com - Investing.com Canada
Repare Therapeutics Shifts Focus to Phase 1 Programs - TipRanks
Repare Therapeutics Seeks Partner Before Advancing Cancer Treatment - MarketWatch
Repare Therapeutics Streamlines Pipeline, Extends Cash Runway to 2027 with Strategic Restructuring - StockTitan
Eton Pharmaceuticals (NASDAQ:ETON) versus Repare Therapeutics (NASDAQ:RPTX) Financial Survey - Defense World
Repare Therapeutics Inc. (NASDAQ:RPTX) Shares Purchased by Stifel Financial Corp - Defense World
Repare Therapeutics stock hits 52-week low at $1.22 - Investing.com
From Crisis to Opportunity: How Advances in Immunotherapy Are Shaping the Oncology Sector - Baystreet.ca
Stifel Nicolaus Has Lowered Expectations for Repare Therapeutics (NASDAQ:RPTX) Stock Price - Defense World
Lifesci Capital Reiterates Market Perform Rating for Repare Therapeutics (NASDAQ:RPTX) - Defense World
Repare Therapeutics (NASDAQ:RPTX) Given "Market Perform" Rating at Lifesci Capital - MarketBeat
LifeSci Capital Downgrades Repare Therapeutics (RPTX) - MSN
Gold Down Over 1%; Inovio Pharmaceuticals Shares Plummet - Benzinga
Why Is Repare Therapeutics Stock Trading Lower On Friday? - Yahoo Finance
Drug duo to Repare lack in gyno cancers? Phase I shows promise - BioWorld Online
Repare Therapeutics Shares Drop 38% Following Phase 1 Trial Results - Yahoo Finance
Repare Therapeutics stock hits 52-week low at $2.35 - Investing.com
Stifel Nicolaus Lowers Repare Therapeutics (NASDAQ:RPTX) Price Target to $4.00 - MarketBeat
Press Release Service: Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial - CRISPR Medicine News
Promising trial results for Repare's cancer drug combo - Investing.com India
Repare stock tanks 38% after Phase 1 data release - MSN
Promising trial results for Repare's cancer drug combo By Investing.com - Investing.com UK
Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial - Business Wire
Press Release Service: Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial - CRISPR Medicine News
Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial - BioSpace
UK desirability has turned a corner in clinical trials - Yahoo Finance
Repare Therapeutics to Present Phase 1 Cancer Trial Data for Novel Drug Combination in December - StockTitan
Analysts' Revenue Estimates For Repare Therapeutics Inc. (NASDAQ:RPTX) Are Surging Higher - Simply Wall St
Industry Analysts Just Made A Notable Upgrade To Their Repare Therapeutics Inc. (NASDAQ:RPTX) Revenue Forecasts - Yahoo Finance
Repare Therapeutics partners with NCI on cancer drug By Investing.com - Investing.com Australia
Press Release Service: Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib - CRISPR Medicine News
Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib - BioSpace
Repare Therapeutics partners with NCI on cancer drug - Investing.com India
Repare Therapeutics Partners with NCI to Advance Breakthrough Cancer Drug Camonsertib | RPTX Stock News - StockTitan
Repare Therapeutics (NASDAQ:RPTX) Earns "Buy" Rating from HC Wainwright - MarketBeat
Repare Therapeutics Reports Q3 2024 Progress and Outlook - TipRanks
Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results - CRISPR Medicine News
Repare Therapeutics Inc (RPTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.81%
자본화:
|
볼륨(24시간):